Sprotafyrirtæki · 27.10.20261 min read
Orphan Therapeutics Accelerator In-Licenses Investigational Gene Therapy Program for Ornithine Transcarbamylase Deficiency from UCL Ventures and Children's Medical Research Institute
Staðbundin vélþýðing · Upprunalegt tungumál heimildar
Summary
OTXL-101, a promising therapy in development for a severe, rare pediatric metabolic condition, becomes the first pipeline program to be in-licensed by Orphan Therapeutics Accelerator (OTXL) CAMBRIDGE, Mass., Oct. 27,…
Upprunalegt tungumál heimildar: PR Newswire UK — News ReleasesOpna upprunalega tilkynningu →